

# Finland

Population 2015

5.5 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.037 (0.037–0.037)	0.68 (0.67–0.68)
Mortality (HIV+TB only)	<0.01 (<0.01–<0.01)	0.01 (0–0.06)
Incidence (includes HIV+TB)	0.31 (0.26–0.35)	5.6 (4.8–6.4)
Incidence (HIV+TB only)	<0.01 (<0.01–<0.01)	0.1 (0.08–0.13)
Incidence (MDR/RR-TB)**	0.017 (<0.01–0.028)	0.31 (0.11–0.51)

Estimated TB incidence by age and sex (thousands)*, 2015			
	0-14 years	> 14 years	Total
Females	0.016 (0.012–0.019)	0.1 (0.071–0.14)	0.12 (0.083–0.16)
Males	<0.01 (<0.01–<0.01)	0.18 (0.14–0.22)	0.19 (0.15–0.23)
Total	0.021 (0.015–0.027)	0.29 (0.26–0.31)	0.31 (0.26–0.35)

TB case notifications, 2015	
Total cases notified	271
Total new and relapse	267
- % tested with rapid diagnostics at time of diagnosis	31%
- % with known HIV status	
- % pulmonary	76%
- % bacteriologically confirmed among pulmonary	82%

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2015	87% (75–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.12 (0.11–0.15)

TB/HIV care in new and relapse TB patients, 2015		
	Number	(%)
Patients with known HIV-status who are HIV-positive	4	
- on antiretroviral therapy	4	100%

Drug-resistant TB care, 2015			
	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			10 (3–17)
Estimated % of TB cases with MDR/RR-TB	5.1% (2.2–9.8)	0% (0–60)	
% notified tested for rifampicin resistance	84%		219
MDR/RR-TB cases tested for resistance to second-line drugs			8
Laboratory-confirmed cases		MDR/RR-TB: 8, XDR-TB: 1	
Patients started on treatment ****		MDR/RR-TB: 8, XDR-TB: 1	

Treatment success rate and cohort size		
	Success	Cohort
New and relapse cases registered in 2014	45%	250
Previously treated cases, excluding relapse, registered in 2014	40%	5
HIV-positive TB cases, all types, registered in 2014		
MDR/RR-TB cases started on second-line treatment in 2013		
XDR-TB cases started on second-line treatment in 2013		

TB preventive treatment, 2015	
% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

TB financing, 2016	
National TB budget (US\$ millions)	

\* Ranges represent uncertainty intervals


\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history

\*\*\*\* Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed


## Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence  
— Notified (new and relapse)  
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2015



Treatment success rate (%)



— New and relapse  
— Retreatment, excluding relapse  
— HIV-positive — MDR/RR-TB — XDR-TB